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increasing systolic blood pressure (HR 1.02, P 0.002), andPredictors of proteinuria and renal failure among women with
decreasing albumin (HR  3.33, P  0.0001) and increasingHIV infection.
creatinine (1.67, P 0.0001) were all associated with the devel-Background. Glomerular disease with proteinuria and renal
opment of renal failure.failure are complications of human immunodeficiency virus
Conclusions. This analysis establishes the associations be-(HIV) infection. While studies suggest risk factors for both
tween both increasing HIV RNA level and decreasing CD4include black race and lower CD4 lymphocyte count, they have
lymphocyte count with the presence of proteinuria and occur-not been established in population-based cohorts. This study
rence of renal failure. Additionally, it demonstrates an associa-examines the risk factors for proteinuria and renal failure in
tion between proteinuria and a positive hepatitis C antibody.a large cohort of HIV-infected women not selected for the
To lessen the presence and progression of renal disease amongpresence of renal disease.
HIV-infected patients, future research should focus on suppres-Methods. This prospective cohort includes 2059 women en-
sion of the HIV RNA level and improvement in CD4 lympho-rolled in the Women’s Interagency HIV study (WIHS). WIHS
cyte count.is a longitudinal study of the clinical course of HIV infection
in which subjects are followed biannually with a detailed exam
including urine analysis, serum creatinine, CD4 lymphocyte
count, and HIV RNA level. Proteinuria was defined as 1 Human immunodeficiency virus (HIV)–related renalon urine dipstick exam on at least two consecutive urine analy-
diseases are the third leading cause of end-stage renalses, and renal failure was defined as a doubling of serum creati-
disease (ESRD) among African Americans aged 20 tonine. Multivariable logistic regression was used to estimate the
associations between clinical variables and the presence of 64 [1]. In early reports, patients with HIV-related renal
proteinuria on initial evaluation in a cross-sectional analysis. diseases had a mortality rate of 50% during the first year
Cox proportional hazards regression was used to estimate the after starting dialysis [2–5]. Recent studies suggest anassociations between clinical variables and time to renal failure
improved survival for patients with antiretroviral ther-among study participants with proteinuria in a prospective
apy [6, 7]. With the increasing prevalence of people livinglongitudinal analysis.
Results. Of 2057 HIV-positive women, 32% (N  671) had with HIV infection, it is projected that the population
proteinuria on initial evaluation. Predictors of proteinuria in- of patients with HIV-infection and ESRD will increase
clude increasing (log) HIV RNA level [odds ratio (OR)  exponentially over the next decade (abstract; Schwartz1.05], black race (OR  2.0), absolute CD4 lymphocyte count
et al, J Am Soc Nephrol 11:165a, 2000) [8]. While the ma-200 cells/mm3 (OR  1.41), and the presence of hepatitis C
jority of HIV-infected patients with renal disease under-antibody (OR  1.27; all P  0.0001). Absolute CD4 lympho-
cyte count 200 cells/mm3 [hazard ratio (HR)  3.57, P  going renal biopsy in the United States have HIV-asso-
0.001], detectable HIV RNA level (HR  2.33, P  0.02), ciated nephropathy (HIVAN) [9], 40% of HIV-infected
patients with kidney disease have other histologic lesions
including membranoproliferative glomerulonephritis, amy-Key words: glomerular disease, AIDS, cohort study, progressive renal
disease, hepatitis C, CD4 lymphocytes, renal failure, WIHS. loid, acute immune-complex glomerulonephritis, cryo-
globulinemia, and IgA nephropathy [10–18].Received for publication May 22, 2001
Among patients with HIVAN, studies suggest that riskand in revised form August 6, 2001
Accepted for publication August 8, 2001 factors for both proteinuria and renal failure include black
race [10, 11, 19–24] and depressed CD4 lymphocyte count 2002 by the International Society of Nephrology
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[9]. Definitive conclusions about these and other risk fac- from enrolled participants. The study enrolled women
with HIV infection tested using ELISA and confirmedtors including gender, mode of infection, and other clini-
cal determinants cannot be made, however, due to the with Western blot (N  2059) as well as at-risk women
who were documented to be seronegative (N  569). Apotential for selection bias introduced in these studies.
Patients were identified for inclusion through inpatient standardized interview-based survey was used at the time
of enrollment to collect data on age, race, gender, coun-referrals to nephrology or by selecting patients under-
going renal biopsy or autopsy. These methods may iden- try of origin, prior medical history, and sexual and drug
use behavior.tify patients with a more aggressive clinical course and
affect the assessment of risk factors associated with pro- Women were evaluated biannually for a maximum of
54 months with a detailed exam to include urine analysis,gression of renal disease. While interpretation of the
epidemiology of HIVAN from these studies is limited CD4 lymphocyte count, and HIV RNA level (measured
biannually) and serum creatinine (measured annually).by their methods, the clinical determinants for the pres-
ence and progression of renal histologic lesions among A Western blot assay done in laboratories approved by
the AIDS Clinical Trial Group was used to determine se-HIV-infected patients other than HIVAN have not been
described. rologic status, and results were reported along with CD4
lymphocyte counts performed locally at baseline. Quan-Observational data suggests that the progression of
HIV-related renal diseases including HIVAN [24–28], titative HIV RNA was determined from ultrafrozen sera
taken at baseline using the nucleic acid sequence-basedmembranous nephropathy [29], and patients with pro-
teinuria but no histologic diagnosis (abstract; Szczech amplification technique (Organon Teknika, Durham, NC,
USA) with a threshold for detection of 4000 copies/mL,et al, J Am Soc Nephrol 10:116, 1999) may be slowed by
the use of antiretroviral medications. Interpretation of as previously described [31]. Serum was assayed by a
second generation enzyme immunoassay for HCV-anti-these studies is similarly limited by the potential for bias
introduced by patient selection methods. Little informa- body [hepatitis C virus encoded antigen (recombinant
c100-3, HC-31, and HC-34) HCV EIA 2.0; Abbott Labo-tion, however, is available on the associations between
either plasma HIV RNA level or CD4 lymphocyte count ratories, Abbott Park, IL, USA]. The WIHS was success-
ful at enrolling and retaining women study participantsand the risk for presence and progression of renal dis-
ease. Our study was therefore undertaken to assess the who were representative of the communities affected by
HIV and AIDS in the US. After five years, the overallclinical and demographic factors including CD4 lympho-
cyte count and HIV RNA level associated with the pres- retention rate in the WIHS was approximately 81% [32].
Data from follow-up visits through 3/31/99 were in-ence of renal disease and the rate of decline in renal
function in a population-based sample of HIV-infected cluded in this analysis.
women. This cohort of women, not selected for the pres-
Definition of variablesence of renal disease, allows for a less biased identifica-
tion and estimation of risk factors, and thereby may Women were described as having proteinuria if at least
two consecutive urine analyses demonstrated the qualita-provide a better understanding of the clinical epidemiol-
ogy and course of these kidney diseases. tive presence of 1 protein. Renal failure was defined
as a doubling of serum creatinine from the measurement
obtained at the initial visit. Women experiencing a dou-
METHODS
bling of serum creatinine were coded as reaching end-
Women’s Interagency HIV Study participants point during the visit at which the increased creatinine
was recorded. Absolute CD4 lymphocyte count was cate-Women in this study were participants in the Women’s
Interagency HIV Study (WIHS). The rationale, organi- gorized as 200 cells/mm3 and 200 cells/mm3. Plasma
HIV RNA level was categorized as nondetectable (4000zation, recruitment, and data collection methods have
been previously described in detail [30]. WIHS is a multi- copies/mL) and detectable (4000 copies/mL). Antiret-
roviral medication use at each follow-up visit was codedcenter, prospective cohort study of the natural history of
HIV infection in women conducted in five metropolitan in two ways. First, specific medications were coded based
on their drug class (that is, nucleoside reverse tran-areas in the United States: Chicago, Los Angeles, New
York City (two sites: Bronx and Brooklyn), San Fran- scriptase inhibitors, NRTI; non-nucleoside reverse tran-
scriptase inhibitors, NNRTI; or protease inhibitors, PI).cisco Bay Area (Northern California), and Washington,
DC. From October 1994 through November 1995, 2628 Second, each participant was coded as either receiving
anti-retroviral therapy based on one of the followingwomen were enrolled in WIHS. Study participants were
recruited from HIV primary care clinics, hospital-based categories: (1) none, (2) monotherapy (a single antiret-
roviral medication), (3) combination therapy (more thanoutpatient infectious diseases clinics, research programs,
community outreach sites, women’s support groups, drug one anti-retroviral agent without a protease inhibitor),
and (4) highly active antiretroviral therapy (HAART;rehabilitation programs, HIV testing sites, and referrals
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more than one antiretroviral agent including at least one (CD4 lymphocyte count 200 cells/mm3 vs. 200 cells/
mm3 and HIV RNA level 4000 copies/mL and 4000protease inhibitor). These variables were recorded at
baseline and at each visit during the course of follow-up. copies/mL) were compared using the log rank test. Cox
proportional hazards regression was used to estimate theFollowing April 1996 (when protease inhibitors first be-
came commercially available), the proportion of the eli- associations between clinical and demographic variables
and time to doubling of creatinine among women withgible cohort reporting first highly active antiretroviral
therapy use (HAART) was 5, 41, 71, and 93% at 6, 12, proteinuria [34]. The models were built using both for-
ward and backward stepwise elimination methods testing18, and 42 months [33].
the variables described above. Plasma HIV RNA level,
Statistical analysis absolute CD4 lymphocyte count, type of therapy (none,
monotherapy, combination therapy, and HAART), andDemographic, clinical, and laboratory parameters were
described at baseline for the patient cohort overall, for the use of medications in each of the antiretroviral classes
(NRTI, NNRTI, and PI) were analyzed as time-varyinggroups of women defined by the presence and absence
of proteinuria, and for groups of women reaching and not covariates. In this manner, values obtained at each visit as
they varied clinically were incorporated into the analysis.reaching the endpoint of doubling of serum creatinine.
Categorical and continuous variables were compared be- All P values reported are two-sided, and all confidence
intervals reported are 95% intervals. All analyses weretween groups using the chi-square and Student t test,
respectively. Due to the distribution of HIV RNA level, performed using Stata (version 5.0; College Station, TX,
USA).the non-parametric Wilcoxon rank-sum test was used to
compare means between groups.
In the initial cross-sectional analysis, the associations
RESULTS
between the presence of established renal disease as de-
Associations with proteinuria at baselinefined by the presence of proteinuria at baseline as a marker
for a glomerular lesion and demographic, clinical, and Demographic and clinical characteristics of HIV-
infected women based on the presence and absence oflaboratory variables were estimated using logistic regres-
sion in both univariate and multivariable analyses. The proteinuria (total N 2057) are shown in Table 1. Thirty-
two percent of women in the cohort (N  671) hadfully adjusted, multivariable logistic regression model
was built using both forward and backward stepwise proteinuria on initial evaluation. In general, women with
proteinuria were more likely than those without protein-elimination methods. Variables tested for significance
included case-mix variables (age, race, and the presence uria to be black (66.2 vs. 50.4%, P  0.0001), have a
greater HIV RNA level (206,011 vs. 145,509 copies/mL,of diabetes mellitus), clinical variables (risk behavior for
HIV acquisition, systolic and diastolic blood pressure), P 0.001), have a lower absolute CD4 lymphocyte count
(338 vs. 385 cells/mm3, P  0.0005), and have a positivebaseline laboratory measurements (absolute CD4 lym-
phocyte count, plasma HIV RNA level, and hepatitis B test for hepatitis C antibody (44.9 vs. 39.9%, P  0.04).
Women with proteinuria also had slightly higher systolicand C serologies), and use and type of antiretroviral
medications. Entry and elimination criteria were set at and diastolic blood pressures (118 vs. 116 and 77 vs. 74
mm Hg, respectively). There were no significant differ-a value of P  0.10. Multivariable risk ratios were calcu-
lated based on model parameter coefficients using stan- ences in the proportion of women with and without pro-
teinuria receiving types of antiretroviral medications atdard methods.
The subsequent longitudinal analysis was restricted to baseline, however, a trend toward a greater use of nucle-
oside reverse transcriptase inhibitors (P  0.06) existedwomen with proteinuria to better identify those women
with glomerular diseases such as HIVAN and the other among women with proteinuria. Few women received
non-nucleoside reverse transcriptase inhibitors (0.6% vs.HIV-related renal lesions, and to minimize inclusion of
women whose renal disease was related to tubulointer- 0.3%, P  0.29, for women with and without proteinuria,
data not shown). No women in either group receivedstitial etiologies such as acute tubular necrosis or allergic
interstitial nephritis. The decision to analyze this sub- protease inhibitors at baseline.
Predictors of proteinuria on initial evaluation usinggroup was made during the design phase of the analysis.
Each patient’s initial study visit was considered her start- multivariable logistic regression are shown in Table 2.
An increase in plasma HIV RNA level by one log (thating time within the analysis. Survival was defined as the
time until doubling of serum creatinine. Women not dou- is, an increase from 40,000 to 400,000) was associated
with a 5% increased risk of having proteinuria on initialbling their serum creatinine by their last visit and women
who died were censored at time of last follow-up. Kaplan- evaluation (OR  1.05, 95% CI 1.03 to 1.07). Similarly,
an absolute CD4 lymphocyte count of 200 cells/mm3Meier survival curves were constructed for women strati-
fied on absolute CD4 lymphocyte count and HIV RNA as compared with 200 cells/mm3 was associated with
an increased risk of proteinuria (OR  1.41, 95% CIlevel, separately. Survival rates for women within strata
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Table 1. Demographic and clinical characteristics on initial evaluation of HIV infected women based on the presence and
absence of proteinuria at baseline (total N  2057a)
Proteinuria
Variable Present Absent P value
N 671 (32%) 1386 (68%)
Ageb years 37.2 (7.7) 36.5 (7.7) 0.04
Race
Blackc 444 (66.2%) 698 (50.4%) 0.0001
Whitec 92 (13.7%) 283 (20.4%)
Hispanic 115 (17.1%) 369 (26.6%)
Other 20 (3.0%) 36 (2.5%)
Creatinineb (initial visit) mg/dL 0.97 (0.63) 0.96 (0.76) 0.83
Plasma HIV RNA levelb copies/mL 206,011 (569,815) 145,509 (612,370) 0.001
Absolute CD4 lymphocyte countb cells/mm3 338 (275) 385 (290) 0.0005
Albuminb mg/dL 4.1 (0.5) 4.2 (0.5) 0.0001
Hepatitis C antibody % positive 301 (44.9%) 553 (39.9%) 0.04
Hepatitis B surface antigen % positive 23 (3.4%) 42 (3%) 0.64
Systolic blood pressureb mm Hg 118 (16.5) 116 (16.0) 0.01
Diastolic blood pressureb mm Hg 77 (11.8) 74 (10.5) 0.0001
Nucleoside reverse transcriptase inhibitord
0 420 (62.6%) 911 (65.7%) 0.06
1 203 (30.3%) 365 (26.3%)
2 42 (6.3%) 104 (7.5%)
3 6 (0.9%) 4 (0.3%)
Risk behavior for HIV acquisition
Intravenous drug use 241 (35.9%) 451 (32.5%) 0.21
Heterosexual risk 266 (39.6%) 583 (42.1%)
Transfusion risk 31 (4.6%) 50 (3.6%)
No identified risk 125 (18.6%) 290 (20.9%)
a Two patients did not have urine analyses available
b Mean (standard deviation)
c Not of Hispanic origin
d N prescribed at initial visit
Table 2. Predictors of proteinuria on initial urine analysis ing endpoint are detailed in Table 3. Women whose
using multivariable logistic regression (N  2057)
serum creatinine doubled during follow-up were in gen-
Variable Odds ratio 95% CI P value eral older at presentation (40.0 vs. 36.7 years, P 0.006),
Log HIV RNA copies/mL 1.05 1.03–1.07 0.0001 more likely to have proteinuria (35 vs. 7, P  0.0001),
Absolute CD4 lymphocyte and present with a higher creatinine (1.42 vs. 0.96 mg/dL,
200 vs. 200 cells/mm3 1.41 1.28–1.54 0.0001
P 0.0001). In addition, women who experienced a dou-Race black as compared
with white 2.00 1.79–2.22 0.0001 bling of serum creatinine were more likely to have a lower
Hepatitis C antibody serum albumin (3.64 vs. 4.18 mg/dL, P  0.0001) and a
positive vs. negative 1.27 1.16–1.35 0.0001
positive hepatitis C antibody (59.5 vs. 40.7%, P  0.01).
Variables tested in the model but not found to be significant include: age, Predictors of renal failure were examined among theserum creatinine, serum albumin, hepatitis B surface antigen, systolic and dia-
stolic blood pressures, risk behavior for HIV acquisition, and use of antiretroviral subset of women with proteinuria at baseline (N 671).
medications. The mean time to doubling of creatinine was 36  14.4
months (range 18 to 54 months) among this group. As
demonstrated in the Kaplan-Meier survival curves (Fig. 1),
women with absolute CD4 lymphocyte count200 cells/1.28 to 1.54). Black as compared with white race was
mm3 have a better renal survival than women with CD4associated with a greater risk of proteinuria (OR  2.0,
lymphocyte count200 cells/mm3 (P 0.0001). The per-
95% CI 1.79 to 2.22). A positive test for a hepatitis C
centage of women not experiencing renal failure at 18,
antibody also was associated with a greater risk of pro- 30, 42, and 54 months was 96%, 89%, 88%, and 84%
teinuria (OR 1.27, 95% CI 1.16 to 1.35; all P 0.0001). for women with CD4 lymphocyte counts200 cells/mm3
and 99%, 98%, 98%, and 95% for women with CD4
Associations with development of renal failure during lymphocyte counts 200 cells/mm3. Women with HIV
prospective follow-up RNA level 4000 copies/mL did not experience signifi-
Forty-two women (2.1%) experienced a doubling of cantly better renal survival in this univariate analysis as
serum creatinine during follow-up. The demographic and compared with women with a HIV RNA level 4000
copies/mL (P  0.31).clinical characteristics of women reaching and not reach-
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Table 3. Demographic and clinical characteristics at the initial evaluation of HIV-infected women who doubled and
did not double serum creatinine during follow-up (N  1956a)
Doubled serum Did not double
Variable creatinine serum creatinine P value
N 42a 1914a
Ageb years 40.0 (8.0) 36.7 (7.7) 0.006
Proteinuria 83.3% 32.9% 0.0001
Race
Blackc 30 1055 0.35
Whitec 7 352
Hispanic 5 455
Other — 51
Creatinineb (initial visit) mg/dL 1.42 (0.85) 0.96 (0.73) 0.0001
Plasma HIV RNA levelb copies/mL 140,373 (260,264) 166,726 (615,136) 0.76
Absolute CD4 lymphocyte countb cells/mm3 323 (221) 371 (287) 0.29
Albuminb mg/dL 3.64 (0.65) 4.18 (0.47) 0.0001
Hepatitis C antibody % positive 59.5% 40.7% 0.01
Hepatitis B surface antigen % positive 2.4% 3.1% 0.79
Systolic blood pressureb mm Hg 117 (17.5) 116 (16.2) 0.87
Diastolic blood pressureb mm Hg 77 (12.6) 75 (11.0) 0.28
Nonnucleoside reverse transcriptase inhibitord
0 97.6% 99.6% 0.04
1 2.4% 0.7%
Protease inhibitord
0 100% 100% 1.0
1 0% 0%
Nucleoside reverse transcriptase inhibitord
0 52.4% 64.5% 0.18
1 42.8% 27.6%
2 4.8% 7.4%
3 0% 0.5%
Risk behavior for HIV acquisition
Intravenous drug use 45.2% 32.9% 0.22
Heterosexual risk 42.9% 42.4%
Transfusion risk 2.4% 4.0%
No identified risk 9.5% 20.6%
a Restricted to women with at least 2 follow-up visits
b Mean (standard deviation)
c Not of Hispanic origin
d N prescribed at initial visit
Table 4. Predictors of renal failure using Cox proportional hazards
regression among patients with proteinuria (N  671)
Hazard ratio 95% CI P value
CD4 lymphocyte count
200 vs. 200 cells/mm3 3.57 1.72–7.14 0.001
HIV RNA level copies/mL
4000 vs. 4000 2.33 1.14–4.76 0.02
Systolic blood pressure mm Hg
per increment of 1 mm Hg 1.02 1.007–1.03 0.002
Albumin mg/dL
per decrement of 1 mg/dL 3.33 2.08–5.26 0.0001
Serum creatinine mg/dL
per increment of 1 mg/dL 1.67 1.53–1.83 0.0001
Variables tested in the model but not found to be significant include: age,
race, hepatitis B surface antigen, hepatitis C antibody, diastolic blood pressure,
risk behavior for HIV acquisition, and use of antiretroviral medications.
Fig. 1. Time to renal failure for women with proteinuria stratified on
category of CD4 lymphocyte count (200 vs.200 cells/mm3) measured
at initial visit (log rank test, P  0.0001).
pared with a CD4 lymphocyte count of 200 cells/mm3
was associated with a hazard ratio for renal failure of
3.57 (95% CI 1.72 to 7.14, P  0.001). A detectableAmong the subset of women with proteinuria at base-
plasma HIV RNA level (4000 copies/mL) as comparedline, predictors of renal failure using multivariate Cox
with an undetectable HIV RNA level (4000 copies/mL)proportional hazards regression are shown in Table 4.
Absolute CD4 lymphocyte count200 cells/mm3 as com- was associated with a risk ratio for renal failure of 2.33
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(95% CI 1.14 to 4.76, P 0.02). Additionally, increasing haps other HIV-related renal diseases represent a direct
infection of the virus within the kidney.systolic blood pressure (RR1.02, 95% CI 1.007 to 1.03,
P  0.002) and decreasing serum albumin were both As participants in the WIHS study were not selected
for the presence of renal disease, this prospective cohortassociated with an increased risk of renal failure (relative
risk  3.33, 95% CI 2.08 to 5.26, P  0.0001). Of note, study is not affected by the selection bias that limits
many of the prior studies that examine the determinantsneither type of therapy (none, monotherapy, combina-
tion therapy, or HAART) or the use of medications in of renal disease in the HIV-infected population [9–11,
19–24]. It allows a more accurate quantification of theeach of the antiretroviral classes (NRTI, NNRTI, or PI)
affected the risk of renal failure. risk of proteinuria and renal failure associated with vari-
ous demographic and clinical parameters.
A positive test for the hepatitis C antibody was a pre-
DISCUSSION
dictor of proteinuria among women in this cohort inde-
This study examines the factors associated with pro- pendent of its association with intravenous drug use or
teinuria and the predictors of renal failure among a large other demographic or clinical variable. Women with pro-
cohort of HIV-infected women. Proteinuria, a marker teinuria and concurrent infection with hepatitis C, how-
for the presence of glomerular disease, was present in ever, did not progress to renal failure at a faster rate
greater than 30% of the cohort. It is associated with an than those women who were not concurrently infected
elevated HIV RNA level, a CD4 lymphocyte count200 with hepatitis C. Independent of HIV infection, the pres-
cells/mm3, black race, and the presence of hepatitis C ence of chronic hepatitis is associated with glomerular
antibody. Among subjects with proteinuria, women with diseases such as mixed cryoglobulinemia, membrano-
CD4 lymphocyte count200 cells/mm3, an elevated HIV proliferative glomerulonephritis, and membranous ne-
RNA level, increasing systolic blood pressure, and de- phropathy [38–43]. These data suggest that concurrent
creasing albumin were more likely to double their serum infection with hepatitis C may result in a greater risk for
creatinine during the course of follow-up. the occurrence of renal disease in the HIV-infected pa-
These findings are consistent with prior studies [10, tient. However, they cannot definitively establish if the
11, 19–24] in which black race and lower CD4 lympho- increased risk of renal disease among patients with con-
cyte count were found to be risk factors for the presence current infections is greater than the sum of their individ-
of renal disease. To our knowledge, this is the first study ual risks (that is, the risk of renal disease is augmented
to demonstrate an association between proteinuria and by the presence of both hepatitis C and HIV infection).
both an elevated HIV RNA level and the presence of While there are no data to suggest differences in the
hepatitis C. Additionally, the associations between an clinical course of HIV-related renal disease based on
undetectable HIV RNA level and greater CD4 lympho- gender, differences in HIV RNA level between genders
cyte count and prolonged renal survival have not been during the course of HIV infection have recently been
previously demonstrated. described. Several studies have demonstrated a lower
In this analysis, no beneficial association between HIV RNA level among women, particularly in early dis-
treatment with antiretroviral medications and renal sur- ease [44–48]. Among this cohort of women, this differ-
vival was demonstrated. The failure to demonstrate this ence will not have an impact on the relationship between
association may be the result of the inclusion of HIV HIV RNA level and progression of nephropathy. The
RNA level and CD4 lymphocyte count in the analysis relationship, however, should be examined among men
as markers of severity of infection and viral replication. with HIV infection to confirm its generalizability.
If suppression of viral replication is the mechanism by While these data offer insight into immunologic mark-
which antiretroviral medications have a beneficial effect ers of a more aggressive clinical course for renal disease,
on renal disease, the inclusion of HIV RNA level and they do have several limitations. Because patients were
CD4 lymphocyte count would be expected to minimize followed with examinations and laboratory tests every
the estimated relationship between these medications six to twelve months, interval censoring limits our ability
and progression of nephropathy by controlling for mech- to define the precise timing of renal failure. However,
anism of effect. Alternatively, the efficacy of antiretro- because the rise in serum creatinine occurred in the inter-
viral medications may not be uniform across antiretro- val prior to its measurement, the delay in its recognition
viral classes (such as, nucleoside reverse transcriptase would result in the appearance of better renal survival
inhibitors, protease inhibitors). Variations in effect due among those groups (such as women with CD4 lympho-
to the use of different antiretrovirals and other issues cyte count200 cells/mm3) who reach endpoint at a faster
such as compliance would bias the investigation of this rate. This would likely bias this analysis against demon-
association toward the null. The significance of HIV strating a difference in survival between groups, thereby
RNA level and CD4 lymphocyte count in this analysis strengthening these results. Further, as protease inhibi-
tors became available following completion of cohort en-supports the hypothesis that HIVAN [35–37] and per-
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